Bicara Therapeutics (BCAX) Net Cash Flow (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Net Cash Flow data on file, last reported at $226.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 920.29% year-over-year to $226.8 million; the trailing twelve-month figure through Mar 2026 stood at -$138.6 million (down 156.34% YoY), and the FY2025 full-year result was -$393.0 million, down 251.59% from the prior year.
• Net Cash Flow for Q1 2026 stood at $226.8 million, up from -$75.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $316.9 million in Q3 2024 and bottomed at -$264.9 million in Q3 2025.
• The 4-year median for Net Cash Flow is -$19.9 million (2024), against an average of $27.9 million.
• The widest annual swing landed in 2025, when Net Cash Flow plunged 183.6%; it then jumped 920.29% in 2026.
• A 4-year view of Net Cash Flow shows it stood at $186.2 million in 2023, then plunged by 116.67% to -$31.0 million in 2024, then plunged by 141.53% to -$75.0 million in 2025, then soared by 402.42% to $226.8 million in 2026.
• The last three Net Cash Flow figures came in at $226.8 million (Q1 2026), -$75.0 million (Q4 2025), and -$264.9 million (Q3 2025), per Business Quant data.

Peer Comparison